aap Implantate AG (0N5A), the Berlin-headquartered medical technology company specialising in traumatology implants, reported a 2% rise in third-quarter 2026 revenue to EUR 3.3 million, surpassing a comparatively strong prior-year quarter. The nine-month cumulative revenue reached EUR 9.3 million, narrowing the year-on-year shortfall to just 1.4%. EBITDA improved across the first nine months and remained above break-even under IFRS, signalling continued operational recovery for the Frankfurt-listed group.

Key Points

  • aap Implantate AG (0N5A), listed on the Frankfurt Stock Exchange General Standard (XETRA: AAQ.DE)
  • Q3 2026 group revenue rose 2% year-on-year to EUR 3.3 million, up from EUR 2.8 million in Q2 2026
  • Nine-month 2026 revenue totalled EUR 9.3 million versus EUR 9.5 million in the same period of 2025; EBITDA above break-even under IFRS
  • Investors may be watching Q4 progress, with the company reporting its highest monthly order intake of the year at the start of the fourth quarter

EMEA and North America Drive Q3 Revenue Gains for aap Implantate AG

EMEA, aap's largest revenue region, grew 3% in Q3 2026 year-on-year to EUR 1.521 million, with Middle East revenue recovering 22% in the quarter, though it remained 51% below the prior-year level for the nine-month period. New product introductions fuelled growth in Spain and Portugal, partially offsetting weakness in South Africa. North America contributed EUR 797,000 in Q3 2026, up 9% in euros and 2% in US dollars, building on a prior-year quarter that had itself grown 18%. The US subsidiary, aap Implants Inc., operates through a network of distribution agents.

LATAM Holds Firm While APAC Faces a Tough Comparative Quarter

The Latin America region matched its Q3 2025 revenue of EUR 832,000, a quarter in which the company had recorded 21% growth. The announcement states that an expanded product portfolio and new markets absorbed the absence of large one-time orders seen in the prior year, providing what management describes as a solid foundation. The Asia-Pacific region posted EUR 184,000 in Q3 2026 revenue, down 14% year-on-year, against an exceptionally strong comparative period in which the region had grown over 200%. aap expressed confidence in further progress in APAC during Q4.

Nine-Month EBITDA Improvement Reflects Cost Discipline Across aap's Operations

Cumulative nine-month 2026 revenue of EUR 9.352 million compared with EUR 9.484 million in the equivalent 2025 period, a decline of approximately 1.4%. Notably, EBITDA continued to improve and remained above break-even under IFRS for the nine-month period, reflecting progress in efficiency and cost control at the Berlin-based manufacturer. aap develops and markets the LOQTEQ® anatomical plate system and a range of cannulated screws, selling directly to German hospitals and through approximately 25 international distributor markets. Its innovation pipeline includes silver-coating antibacterial technology and magnesium-based implants.

aap Enters Q4 2026 With Highest Monthly Order Intake of the Year

The company stated that the fourth quarter commenced with the highest monthly order intake recorded in 2026, which the announcement frames as a positive leading indicator. aap indicated confidence in further reducing its cumulative revenue shortfall relative to 2025 across both LATAM and APAC in Q4. An investor presentation containing the corresponding outlook was set to be published on the company's website from 11 November 2026. Investors may be watching whether the Q4 order momentum translates into a full-year revenue recovery relative to the 2025 baseline.